Reduction of direct and indirect costs in patients with AS receiving etanercept: results from an open-label 36-week extension of the ASCEND study in four European countries.
OBJECTIVE
To characterize the impact of etanercept (ETN) in AS on cost, work productivity and quality of life (QoL).


METHODS
A Phase 4, open-label, multi-centre (UK, Scandinavia) extension study in AS. Eligible subjects (n = 84) were treated for 36-52 weeks with ETN 50 mg s.c. once weekly. Analysis included direct costs (transformed out-patient and in-patient care elements), indirect costs (sick leave and lost working days), efficacy and QoL.


RESULTS
Annualized direct and indirect costs decreased (55.5%, P ≤ 0.008) during ETN treatment, as did out-patient and in-patient episodes (physiotherapist/physician visits, P = 0.012). Work productivity and QoL increased.


CONCLUSIONS
ETN therapy significantly reduces direct and indirect health-care costs and increases work ability and QoL in AS. Trial Registration. EUDRACT, https://eudract.ema.europa.eu/, 2006-001061-42.
Institute for Chronic Diseases and Ageing, University of Liverpool, Liverpool, UK. r.j.moots@liverpool.ac.uk
Robert J
RJ
Moots
Andrew J K
AJ
Ostor
Anne G R
AG
Loft
Pentti
P
Järvinen
Per
P
Larsson
Mats
M
Ekelund
Alan
A
Reynolds
Danuta
D
Kielar
Rose-Marie
RM
Lindkvist
Susanne
S
Qvitzau
D000328:Adult; D000368:Aged; D018501:Antirheumatic Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000191:economics; D004526:Efficiency; D004651:Employment; D000068800:Etanercept; D005260:Female; D017048:Health Care Costs; D006801:Humans; D007074:Immunoglobulin G / Q000008:administration & dosage* / Q000009:adverse effects / Q000191:economics; D008297:Male; D008875:Middle Aged; D011788:Quality of Life; D018124:Receptors, Tumor Necrosis Factor / Q000008:administration & dosage*; D018582:Sick Leave / Q000706:statistics & numerical data; D013167:Spondylitis, Ankylosing / Q000188:drug therapy* / Q000191:economics; D016896:Treatment Outcome; D055815:Young Adult
D018501:Antirheumatic Agents; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D000068800:Etanercept